Timothy Piatkowski, a National Health and Medical Research Council emerging leadership fellow from the school of public health at the University of Queensland, Australia, tells us that the synthetic peptide trend is comparable to the rise of GLP-1 weight loss drugs as seen in the case of the unapproved triple agonist retatrutide
Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C: Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses
Unless you're a licensed and approved dealer of the real thing, don't mention the trademark's name anywhere near your product pages
Heres what the science says.